NVAXライブシグナル | Getagraph.comで利益を最大化

売る 66673 min ago

@ $5.28

発行日: 14 3月 2024 @ 03:02

リターン: -22.55%

前回のシグナル: 3月 14 - 02:12

前回のシグナル: 買う

リターン: 1.36 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
本日の出来高	3.01M
平均出来高	7.13M
時価総額	572.41M
EPS	$0 ( 2024-02-28 )
次の収益日	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.99
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

ボリューム相関

長: -0.13 (neutral)

短: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Novavax Inc 相関 - 通貨/商品

-0.29
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.32
( neutral )

Novavax Inc 財務諸表

Annual	2023
収益:	$983.71M
総利益:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
収益:	$983.71M
総利益:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
収益:	$1.60B
総利益:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
収益:	$1.15B
総利益:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.